Allegheny Technologies Net Income $35.3M For 3Q (ATI, BMY)
10/26/2012

[Bristol-Myers Squibb reported financial results for the third quarter of 2012, adjusted 2012 GAAP and confirmed non-GAAP EPS guidance]

Online PR News – 26-October-2012 – Las Vegas, NV – Allegheny Technologies Incorporated (NYSE: ATI) ATI ("Allegheny Technologies") reported net income for the third quarter 2012 of $35.3 million, or $0.32 per share, on sales of $1.22 billion. In the third quarter 2011, ATI reported net income of $62.3 million, or $0.56 per share, on sales of $1.35 billion. For the nine months ended September 30, 2012, net income was $147.9 million, or $1.32 per share, on sales of $3.93 billion. For the nine months ended September 30, 2011, net income was $182.6 million, or $1.68 per share, on sales of $3.93 billion. Allegheny Technologies Incorporated (NYSE: ATI) is one of the largest and most diversified specialty metals producers in the world with revenues of approximately $5.2 billion for the last twelve months. ATI has approximately 11,300 full-time employees world-wide who use innovative technologies to offer global markets a wide range of specialty metals solutions. Our major markets are aerospace and defense, oil and gas/chemical process industry, electrical energy, medical, automotive, food equipment and appliance, machine and cutting tools, and construction and mining. Our products include titanium and titanium alloys, nickel-based alloys and superalloys, grain-oriented electrical steel, stainless and specialty steels, zirconium, hafnium, and niobium, tungsten materials, forgings, castings and fabrication and machining capabilities. The ATI website is www.ATImetals.com.

Bristol-Myers Squibb Company (NYSE: BMY) BMY ("Bristol-Myers Squibb") reported financial results for the third quarter of 2012, adjusted 2012 GAAP and confirmed non-GAAP EPS guidance. Bristol-Myers Squibb posted third quarter 2012 net sales of $3.7 billion, a decrease of 30% compared to the same period a year ago, following the U.S. patent expiration of Avapro®/Avalide® in March 2012 and Plavix® in May 2012. Excluding Plavix and Avapro/Avalide, net sales grew by 7% compared to the third quarter of 2011. Bristol-Myers Squibb is adjusting its 2012 GAAP EPS guidance range to $0.95 to $1.05, from $1.78 to $1.88, and confirming its 2012 non-GAAP EPS range of $1.90 to $2.00, guiding to the upper end of the range. Bristol-Myers Squibb Company (NYSE: BMY) is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com

Crown Equity Holdings Inc. (CRWE) CRWE AD-Services, a division of CRWE is a full service multimedia advertising company specializing in internet marketing. Their goal is to provide you with a customized advertising blue print using their expansive resources. CRWE Ad Services (www.crwe-adservices.com ) provides modern and unique advertising campaigns. They are dedicated to offering the most cost effective advertising solutions. Furthermore, CRWE Tube (www.crwetube.com ), a video sharing site of CRWE, allows billions of people around the world to upload, watch and share original videos. With online videos continuing to experience explosive, viral growth and the web rapidly moving from text to video, businesses will need to adapt to the shift in video distribution technology or quickly become irrelevant to their consumers who anticipate seeing video everywhere online. CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. Crown Equity Holdings advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. For more information about Crown Equity Holdings Inc. visit www.crownequityholdings.com.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: CRWEWallStreet.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. (Read Full Disclaimer at http://crwewallstreet.com/disclaimer).